Shanghai Henlius Biotech, Inc. (2696.HK)
Develops biologic drugs to treat cancer, autoimmune diseases, and eye conditions
53.25+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-19.3%
The outlook
Shanghai Henlius Biotech is trading near its 52-week low with analysts strongly bullish, posting an average price target about 92% above the current price. The stock sits below both its 50- and 200-day moving averages, suggesting a weakened near-term trend. The disconnect between strong analyst sentiment and the stock's depressed technical position reflects mixed signals.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +92% vs current price
Analyst price target
~12-month · 6 analysts102.47average target+92.4% vs now
Now 53.25
Low 91.08High 119.20
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$29.03B
52-wk high
92.00
52-wk low
50.25
50-day avg
62.22
200-day avg
66.62
Trailing P/E
30.4